Inhibition of colon cancer K-RasG13D mutation reduces cancer cell proliferation but promotes stemness and inflammation via RAS/ERK pathway
K-Ras is a well-studied oncogene, and its mutation is frequently found in epithelial cancers like pancreas, lung, and colorectal cancers. Cancer cells harboring K-Ras mutations are difficult to treat due to the drug resistance and metastasis properties. Cancer stem cells (CSCs) are believed the majo...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-10-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2022.996053/full |
| _version_ | 1811197384322973696 |
|---|---|
| author | Yan Qi Yan Qi Hong Zou Hong Zou XiaoHui Zhao Joanna Kapeleris Michael Monteiro Feng Li Zhi Ping Xu Yizhen Deng Yanheng Wu Ying Tang Wenyi Gu Wenyi Gu |
| author_facet | Yan Qi Yan Qi Hong Zou Hong Zou XiaoHui Zhao Joanna Kapeleris Michael Monteiro Feng Li Zhi Ping Xu Yizhen Deng Yanheng Wu Ying Tang Wenyi Gu Wenyi Gu |
| author_sort | Yan Qi |
| collection | DOAJ |
| description | K-Ras is a well-studied oncogene, and its mutation is frequently found in epithelial cancers like pancreas, lung, and colorectal cancers. Cancer cells harboring K-Ras mutations are difficult to treat due to the drug resistance and metastasis properties. Cancer stem cells (CSCs) are believed the major cause of chemotherapeutic resistance and responsible for tumor recurrence and metastasis. But how K-Ras mutation affects CSCs and inflammation is not clear. Here, we compared two colon cancer cell lines, HCT-116 and HT-29, with the former being K-RasG13D mutant and the latter being wildtype. We found that HCT-116 cells treated with a K-Ras mutation inhibitor S7333 formed significantly more tumor spheroids than the untreated control, while the wild type of HT-29 cells remained unchanged. However, the size of tumor spheroids was smaller than the untreated controls, indicating their proliferation was suppressed after S7333 treatment. Consistent with this, the expressions of stem genes Lgr5 and CD133 significantly increased and the expression of self-renewal gene TGF-β1 also increased. The flow cytometry analysis indicated that the expression of stem surface marker CD133 increased in the treated HCT-116 cells. To understand the pathway through which the G13D mutation induced the effects, we studied both RAS/ERK and PI3K/Akt pathways using specific inhibitors SCH772984 and BEZ235. The results indicated that RAS/ERK rather than PI3K/Akt pathway was involved. As CSCs play the initial role in cancer development and the inflammation is a vital step during tumor initiation, we analyzed the correlation between increased stemness and inflammation. We found a close correlation of increased Lgr5 and CD133 with proinflammatory factors like IL-17, IL-22, and IL-23. Together, our findings suggest that K-RasG13D mutation promotes cancer cell growth but decreases cancer stemness and inflammation thus tumorigenesis and metastasis potential in colon cancer. Inhibition of this mutation reverses the process. Therefore, care needs be taken when employing targeted therapies to K-RasG13D mutations in clinics. |
| first_indexed | 2024-04-12T01:12:40Z |
| format | Article |
| id | doaj.art-e51cd928dc414281a8adfef94658b0c4 |
| institution | Directory Open Access Journal |
| issn | 1663-9812 |
| language | English |
| last_indexed | 2024-04-12T01:12:40Z |
| publishDate | 2022-10-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj.art-e51cd928dc414281a8adfef94658b0c42022-12-22T03:54:03ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122022-10-011310.3389/fphar.2022.996053996053Inhibition of colon cancer K-RasG13D mutation reduces cancer cell proliferation but promotes stemness and inflammation via RAS/ERK pathwayYan Qi0Yan Qi1Hong Zou2Hong Zou3XiaoHui Zhao4Joanna Kapeleris5Michael Monteiro6Feng Li7Zhi Ping Xu8Yizhen Deng9Yanheng Wu10Ying Tang11Wenyi Gu12Wenyi Gu13Department of Pathology, Central People’s Hospital of Zhanjiang and Zhanjiang Central Hospital, Guangdong Medical University, Zhanjiang, ChinaAustralian Institute for Bioengineering and Nanotechnology (AIBN), University of Queensland (UQ), Brisbane, QLD, AustraliaAustralian Institute for Bioengineering and Nanotechnology (AIBN), University of Queensland (UQ), Brisbane, QLD, AustraliaDepartment of Pathology, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, ChinaAustralian Institute for Bioengineering and Nanotechnology (AIBN), University of Queensland (UQ), Brisbane, QLD, AustraliaAustralian Institute for Bioengineering and Nanotechnology (AIBN), University of Queensland (UQ), Brisbane, QLD, AustraliaAustralian Institute for Bioengineering and Nanotechnology (AIBN), University of Queensland (UQ), Brisbane, QLD, AustraliaDepartment of Pathology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, ChinaAustralian Institute for Bioengineering and Nanotechnology (AIBN), University of Queensland (UQ), Brisbane, QLD, AustraliaGillion Biotherapeutics Ltd., Guangzhou Huangpu Industrial Zoon, Guangzhou, ChinaGillion Biotherapeutics Ltd., Guangzhou Huangpu Industrial Zoon, Guangzhou, ChinaScience and Technology Innovation Center, Guangzhou University of Chinese Medicine, Guangzhou, ChinaAustralian Institute for Bioengineering and Nanotechnology (AIBN), University of Queensland (UQ), Brisbane, QLD, AustraliaGillion Biotherapeutics Ltd., Guangzhou Huangpu Industrial Zoon, Guangzhou, ChinaK-Ras is a well-studied oncogene, and its mutation is frequently found in epithelial cancers like pancreas, lung, and colorectal cancers. Cancer cells harboring K-Ras mutations are difficult to treat due to the drug resistance and metastasis properties. Cancer stem cells (CSCs) are believed the major cause of chemotherapeutic resistance and responsible for tumor recurrence and metastasis. But how K-Ras mutation affects CSCs and inflammation is not clear. Here, we compared two colon cancer cell lines, HCT-116 and HT-29, with the former being K-RasG13D mutant and the latter being wildtype. We found that HCT-116 cells treated with a K-Ras mutation inhibitor S7333 formed significantly more tumor spheroids than the untreated control, while the wild type of HT-29 cells remained unchanged. However, the size of tumor spheroids was smaller than the untreated controls, indicating their proliferation was suppressed after S7333 treatment. Consistent with this, the expressions of stem genes Lgr5 and CD133 significantly increased and the expression of self-renewal gene TGF-β1 also increased. The flow cytometry analysis indicated that the expression of stem surface marker CD133 increased in the treated HCT-116 cells. To understand the pathway through which the G13D mutation induced the effects, we studied both RAS/ERK and PI3K/Akt pathways using specific inhibitors SCH772984 and BEZ235. The results indicated that RAS/ERK rather than PI3K/Akt pathway was involved. As CSCs play the initial role in cancer development and the inflammation is a vital step during tumor initiation, we analyzed the correlation between increased stemness and inflammation. We found a close correlation of increased Lgr5 and CD133 with proinflammatory factors like IL-17, IL-22, and IL-23. Together, our findings suggest that K-RasG13D mutation promotes cancer cell growth but decreases cancer stemness and inflammation thus tumorigenesis and metastasis potential in colon cancer. Inhibition of this mutation reverses the process. Therefore, care needs be taken when employing targeted therapies to K-RasG13D mutations in clinics.https://www.frontiersin.org/articles/10.3389/fphar.2022.996053/fullK-RasG13D mutationcolon cancercancer stem cellstumor spheroidERK pathwayPI3K/Akt pathway |
| spellingShingle | Yan Qi Yan Qi Hong Zou Hong Zou XiaoHui Zhao Joanna Kapeleris Michael Monteiro Feng Li Zhi Ping Xu Yizhen Deng Yanheng Wu Ying Tang Wenyi Gu Wenyi Gu Inhibition of colon cancer K-RasG13D mutation reduces cancer cell proliferation but promotes stemness and inflammation via RAS/ERK pathway Frontiers in Pharmacology K-RasG13D mutation colon cancer cancer stem cells tumor spheroid ERK pathway PI3K/Akt pathway |
| title | Inhibition of colon cancer K-RasG13D mutation reduces cancer cell proliferation but promotes stemness and inflammation via RAS/ERK pathway |
| title_full | Inhibition of colon cancer K-RasG13D mutation reduces cancer cell proliferation but promotes stemness and inflammation via RAS/ERK pathway |
| title_fullStr | Inhibition of colon cancer K-RasG13D mutation reduces cancer cell proliferation but promotes stemness and inflammation via RAS/ERK pathway |
| title_full_unstemmed | Inhibition of colon cancer K-RasG13D mutation reduces cancer cell proliferation but promotes stemness and inflammation via RAS/ERK pathway |
| title_short | Inhibition of colon cancer K-RasG13D mutation reduces cancer cell proliferation but promotes stemness and inflammation via RAS/ERK pathway |
| title_sort | inhibition of colon cancer k rasg13d mutation reduces cancer cell proliferation but promotes stemness and inflammation via ras erk pathway |
| topic | K-RasG13D mutation colon cancer cancer stem cells tumor spheroid ERK pathway PI3K/Akt pathway |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2022.996053/full |
| work_keys_str_mv | AT yanqi inhibitionofcoloncancerkrasg13dmutationreducescancercellproliferationbutpromotesstemnessandinflammationviaraserkpathway AT yanqi inhibitionofcoloncancerkrasg13dmutationreducescancercellproliferationbutpromotesstemnessandinflammationviaraserkpathway AT hongzou inhibitionofcoloncancerkrasg13dmutationreducescancercellproliferationbutpromotesstemnessandinflammationviaraserkpathway AT hongzou inhibitionofcoloncancerkrasg13dmutationreducescancercellproliferationbutpromotesstemnessandinflammationviaraserkpathway AT xiaohuizhao inhibitionofcoloncancerkrasg13dmutationreducescancercellproliferationbutpromotesstemnessandinflammationviaraserkpathway AT joannakapeleris inhibitionofcoloncancerkrasg13dmutationreducescancercellproliferationbutpromotesstemnessandinflammationviaraserkpathway AT michaelmonteiro inhibitionofcoloncancerkrasg13dmutationreducescancercellproliferationbutpromotesstemnessandinflammationviaraserkpathway AT fengli inhibitionofcoloncancerkrasg13dmutationreducescancercellproliferationbutpromotesstemnessandinflammationviaraserkpathway AT zhipingxu inhibitionofcoloncancerkrasg13dmutationreducescancercellproliferationbutpromotesstemnessandinflammationviaraserkpathway AT yizhendeng inhibitionofcoloncancerkrasg13dmutationreducescancercellproliferationbutpromotesstemnessandinflammationviaraserkpathway AT yanhengwu inhibitionofcoloncancerkrasg13dmutationreducescancercellproliferationbutpromotesstemnessandinflammationviaraserkpathway AT yingtang inhibitionofcoloncancerkrasg13dmutationreducescancercellproliferationbutpromotesstemnessandinflammationviaraserkpathway AT wenyigu inhibitionofcoloncancerkrasg13dmutationreducescancercellproliferationbutpromotesstemnessandinflammationviaraserkpathway AT wenyigu inhibitionofcoloncancerkrasg13dmutationreducescancercellproliferationbutpromotesstemnessandinflammationviaraserkpathway |